TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with RA for greater than or equal to (\>/=6) months receiving 162 mg tocilizumab PFS-NSD for \>/=8 weeks and who are suitable for continued treatment at their currently prescribed dose~* CGs and professionally qualified HCPs who are able and willing to administer the injection~Exclusion Criteria:~* RA: Functional status Class IV~* RA: Neuropathies or other conditions that might interfere with pain evaluation~* RA: Pregnant or breastfeeding~* RA: Low neutrophil or platelet count at last laboratory assessment~* RA: Elevated liver enzymes at last laboratory assessment~* Current participation in another interventional clinical trial~* Criteria that might give the participant/CG/HCP an advantage in injection tasks such as employment in the pharmaceutical industry, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caregivers (Type: EXPERIMENTAL): CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
- Healthcare Professionals (Type: EXPERIMENTAL): HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
- RA Group 1 (Self-Administration) (Type: EXPERIMENTAL): Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
- RA Group 2 (Administration by CG) (Type: OTHER): CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
- RA Group 3 (Administration by HCP) (Type: OTHER): HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable angina~* candidates to drug eluting stent implantation~* High on-treatment platelet reactivity according to a point-of-care platelet function test~Exclusion Criteria:~* chronic therapy with statins~* inability to provide informed consent~* intolerance to statins~* acute or chronic liver failure or ALT \> 2 times ULN~* known myopathy~* CKD stage IV or dialysis treatment~* pregnancy or breast-feeding~* malignancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin-Clopidogrel group (Type: EXPERIMENTAL): Patients who receive Atorvastatin 80 mg/day and Clopidogrel 150 mg/day
- Clopidogrel group (Type: ACTIVE_COMPARATOR): Patients who receive clopidogrel 150 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient greater than or equal to 18 years of age,~* non-smokers,~* diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal,~* stable use of Beta agonist~* daily use of inhaled steroids for one year~Exclusion Criteria:~* Patients with other significant diseases other than asthma, requiring oxygen,~* intubated within 5 years,~* asthma exacerbation within 6 weeks of trial,~* use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,~* participating in another interventional trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous participation in the Study Of Pharmacogenetics In Ethnically Diverse Populations (SOPHIE) study.~* Between the ages of 18 and 40.~* Possess a specific OCT1 genotype.~Exclusion Criteria:~* Taking any medications other than vitamins~* Individuals with anemia (hemoglobin \< 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL)~* Pregnant at time of study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- OCT1-variant Group (Type: EXPERIMENTAL): Subjects with OCT1-variant alleles will be dosed with 2 doses of Metformin
- OCT1-reference Group (Type: EXPERIMENTAL): Subjects with OCT1-reference alleles will be dosed with 2 doses of Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Autologous MSC Infusion to Treat Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of symptomatic epilepsy,~* Disease progression for the last 1-3 years,~* Resistance of epilepsy to therapy with carbamazepine, valproic acid, topiramate, lamotrigine, and phenobarbital (anti-epileptic drugs/AEDs) as monotherapies or combination therapies;~* Signed informed consent~Exclusion Criteria:~* Central nervous system inflammatory disorders (meningoencephalitis of viral or parasite origin),~* Chronic decompensated psychoses ,dementia, social disadaptation,~* Central nervous system tumours.~* Blood positivity for hepatitis B or C or HIV infection;~* According to the judgment of the researchers, subjects who were unable to complete the study or may not have been able to comply with the requirements of this study (due to administrative or other reasons).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- study group (Type: EXPERIMENTAL): Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs \[AEDs\]) and receiving autologous mesenchymal stem cells
- control group (Type: NO_INTERVENTION): Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coloplast DialogueStudy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Signed informed consent before any study related activities~* Subjects with a colostomy, ileostomy or urostomy~* Subjects must have had their ostomy for at least 6 months~* Subjects must have mental capacity to understand the study and questionnaires~* Subjects must be at least 18 years of age.~Exclusion criteria~* Women who are pregnant or breast-feeding~* Subjects who have more than one ostomy~* Subjects with an ostomy who use plug~* Participation in other studies at the same time~* Previous participation in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Infusion in Community-acquired Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients aged 18 to 100 years with a community-acquired pneumonia.~Criteria to determine a community-acquired pneumonia:~* Chest radiograph showing new opacities~* In combination with two of the following findings:~  * Cough~ * Production of sputum~ * Temp \>38,0 °C or \<36,0 °C~ * Audible abnormalities by chest examination compatible with pneumonia~ * Leukocytosis (\>10.000 cells/mm3), leftward shift (\>10%) or leukopenia (\<4000 cells/mm3)~ * CRP \> 15 mg/dl (three times upper limit of normal)~Exclusion Criteria:~* o The following groups are excluded:~  * Immunocompromised patients:~    * Patients with a known congenital or achieved immunodeficiency.~   * Patients who received chemotherapy less than 6 weeks ago.~   * Patients who received corticosteroids in the last 6 weeks.~   * Patients who received immunosuppressive medication in the last 6 weeks. (like cyclosporine, cyclofosfamide, azathioprine)~   * Patients with COPD who are on systemic corticosteroids for COPD.~   * Patients who require ICU treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): dexamethasone
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Video System in Improving Learning of Tracheal Intubation Using Standard Laryngoscopy Among Novices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Students:~Inclusion criteria for the medical student:~* Medical student or intern rotating through the anesthesiology department~Exclusion criteria for the medical student:~* Previous attempts of laryngoscopy in humans~* Subject who refuses participation~Patients:~Inclusion Criteria:~* Age 18 -75 years of age~* ASA PS I, II~* Procedure that will require General anesthesia with tracheal intubation~Exclusion Criteria:~* Age \< 18 years old or greater than 75 years of age~* Patient or student who refuses participation~* ASA Physical status class III or greater~* History of lung disease~* History of obstructive sleep apnea~* History of difficult intubation~* Evidence of possible difficult airway (Mallampati Class \>2, TMH distance \<6 cm, mouth opening \<4 cm and limited neck mobility)~* Unanticipated difficult laryngoscopy (defined by inability of the attending anesthesiology to intubate after 2 attempts)~* Patients at risk for aspiration~* Patients with BMI greater than 35~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: OTHER): Control group, taught with a standard Macintosh laryngoscope
- Study group (Type: EXPERIMENTAL): Study group taught with the Airtraq video laryngoscope

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Major Depressive Disorder, single or recurrent episode, according to DSM-IV criteria~* HAM-D17 total score \> or = 22 at Screening and Baseline~* CGI-Severity score \> or = 4 at Screening and Baseline~* Only patients who complete the core protocol are eligible to participate in the Open-Label Extension Phase~Exclusion Criteria:~* History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder~* Any current Axis I disorder other than major depressive disorder which is the focus of treatment~* Substance or alcohol abuse in the last 30 days, dependence in the last 6 months~* Concomitant psychotropic medication, including herbal preparations and melatonin~* Psychotherapy of any type~* Female patients of childbearing potential who are not using effective contraception~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DP13 - A Phase II Study in Patients With Primary Aldosteronism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients with a guideline-recommended diagnosis of primary aldosteronism~Exclusion Criteria:~Patients with primary aldosteronism and~* hyperkalemia~* prolonged QT intervals~* refusal of special contraception measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 4 mg DP13 daily (Type: EXPERIMENTAL): DP13 for 8 weeks
- 8 mg DP13 daily (Type: EXPERIMENTAL): DP13 for 8 weeks
- 12 mg DP13 daily (Type: EXPERIMENTAL): DP13 for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose of Dual Therapy Plus Metronidazole for Helicobacter Pylori RescueTreatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with non-ulcer functional dyspepsia or peptic ulcer disease~* Ability and willingness to participate in the study and to sign and give informed consent~* Confirmed H. pylori infection and with previous treatment failure~Exclusion Criteria:~* Less than 18 years old or older than 80 years~* With previous gastric surgery~* Major systemic diseases~* Pregnancy or lactation~* Allergy to any of the study drugs~* Administration of antibiotics, bismuth,antisecretory drugs in 8 weeks prior to inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dual therapy (Type: ACTIVE_COMPARATOR): Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days
- Metronidazole plus dual therapy (Type: EXPERIMENTAL): Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria include:~1. Patient with dementia of Alzheimer's type, according to the Diagnostic and Statistical Manual of Mental Disorders criteria (DSM-IV)~2. Patient with probable Alzheimer' disease according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria (NINCDS-ADRDA)~3. Patient with MMSE ≥ 12 and ≤ 25 at baseline~4. Patient treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose of memantine for a minimum of 6 months at baseline, with no changes foreseen in therapy throughout the study.~Exclusion criteria include:~1. Patient with any other cause of dementia not due to Alzheimer's disease.~2. Patient with Alzheimer disease with severe forms of delusions or delirium (patients with light and mild forms of delusions and delirium will be allowed in the study).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Masitinib escalating dose (Type: EXPERIMENTAL): Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment
- Masitinib fixed dose (4.5 mg/kg/day) (Type: EXPERIMENTAL): Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.
- Masitinib fixed dose (3.0 mg/kg/day) (Type: EXPERIMENTAL): Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.
- Placebo (escalating dose) (Type: PLACEBO_COMPARATOR): Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment
- Placebo (fixed dose) (Type: PLACEBO_COMPARATOR): Participants receive fixed dose placebo, given orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No history of genital warts, vulvar intraepithelial neoplasia (VIN), or vaginal intraepithelial neoplasia (VaIN)~* Not pregnant and agrees to use effective contraception through Month 7 of the study~* Additional criteria applied~Exclusion Criteria:~* Pregnant~* Concurrently enrolled in a clinical study involving collection of cervical specimens~* Previously received any HPV vaccine~* History of severe allergic reaction that required medical intervention~* Received any immune globulin or blood-derived products within 3 months prior to the first study injection~* History of splenectomy, known immune disorders, or receiving immunosuppressives~* Immunocompromised or diagnosed with human immunodeficiency virus (HIV) infection~* Known thrombocytopenia or any coagulation disorders that could contraindicate intramuscular injections~* History of recent or ongoing alcohol or drug abuse~* Prior treatment for genital warts, VIN, or VaIN~* History of cervical disease (ie, surgical treatment for cervical lesions)~* Hysterectomy

- Gender: FEMALE
- Minimum Age: 24 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- qHPV Vaccine in Base Study (Type: EXPERIMENTAL): Participants received blinded qHPV vaccination at Day 1, Month 2, and Month 6 of the Base Study
- Placebo in Base Study (Type: PLACEBO_COMPARATOR): Participants received blinded placebo at Day 1, Month 2, and Month 6 in the Base Study. They were eligible to receive open-label qHPV vaccine in Extension 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male, age below 6 years of age at the time of signing informed consent~* Diagnosis of severe haemophilia A (FVIII activity level 1%) based on medical records or central laboratory results~* No prior use of purified clotting factor products (5 previous exposures to blood components is acceptable)~Exclusion Criteria:~* Any history of FVIII inhibitor (defined by medical records) - Known or suspected hypersensitivity to trial product or related products~* Previous participation in this trial. Participation is defined as first dose administered of trial product~* Receipt of any investigational medicinal product within 30 days before screening~* Congenital or acquired coagulation disorder other than haemophilia A~* Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise the patient's safety or compliance with the protocol~* Patient's parent(s')/legally acceptable representative (LAR(s')) mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- 50 EDs (exposure days) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete